
- Tissue
- 外周血
- Disease
- 腺癌
- Metastatic site
- 不適用(來自林奇綜合徵結直腸癌患者的EBV轉化B細胞淋巴細胞樣細胞)
- Synonyms
- B-LCL CO285, Bc HROC285
Documents
B-LCL-HROC285
Cell line · Product number 300869
B-LCL-HROC285 is an Epstein-Barr virus (EBV) transformed B lymphocyte cell line derived from a patient, who had colon adenocarcinoma associated with Lynch...
Recommended (freshest lot)
01General information
- Description
B-LCL-HROC285 是一種源自一名患有林奇症候群相關結腸腺癌患者的、經愛潑斯坦-巴爾病毒(EBV)轉化的 B 淋巴細胞系。 此特定類型的結腸癌與遺傳性非息肉性結直腸癌(HNPCC)有關,通常由 DNA 錯配修復基因的突變所引起。 B-LCL-HROC285 細胞系不僅能用於研究 B 細胞中與 EBV 相關的轉化過程,還能深入了解與癌症相關的免疫反應。
B-LCL-HROC285 為理解免疫系統與癌細胞之間的相互作用提供了一種寶貴的工具,特別是轉化 B 細胞如何與林奇綜合徵所引發的結直腸癌中的免疫環境相互作用。 由於其遺傳背景以及已知會影響 B 細胞增殖與克隆選擇的 EBV 轉化過程,該細胞系對於免疫學和腫瘤學研究具有實用價值。
- Tissue
- 外周血
- Disease
- 腺癌
- Metastatic site
- 不適用(來自林奇綜合徵結直腸癌患者的EBV轉化B細胞淋巴細胞樣細胞)
- Applications
- T 細胞與自然殺傷細胞(NK 細胞)檢測;HLA 分型;林奇症候群免疫學;與錯配修復(MMR)缺陷相關的免疫反應;細胞毒性 T 細胞(CTL)檢測標靶細胞;高風險卵巢癌(HROC)生物樣本庫中與患者配對的研究
- Synonyms
- B-LCL CO285
- Bc HROC285
02Classification
- Organism
- Human
- Sex
- Female
- Growth properties
- Suspension
- GMO status
- GMO-S2
- GMO status details
- GMO-S2: This B-LCL contains a stably maintained EBV episome (EBNA-1/-2/-3, LMP-1/-2). EBV is classified as risk group 2; BSL-2 containment required. This classification applies within Germany; regulations may differ elsewhere.
- Biosafety level
- 2
03Characteristics
- Morphology
- 圓形細胞
- Cell type
- B 淋巴母細胞
04Identifiers
- Citation
- B-LCL-HROC285(Cytion 型號 300869)
- NCBI TaxID
- 9606
- Cellosaurus
- Not assigned
05Expression and susceptibility
- Viruses
- 轉化體:EBV
06Handling and culture
- Culture medium
- RPMI 1640,含 2.0 mM 穩定谷氨醯胺,含 2.0 g/L NaHCO₃(Cytion 產品編號 820700a)
- Incubation atmosphere
37°C,5% CO₂,加濕環境。
- Supplements
- 在培養基中加入 10% 經熱滅活的胎牛血清
- Subculturing
- 透過移液管上下吸放,輕柔地將燒瓶中的細胞懸浮液均質化,然後取一份具代表性的樣本,以測定每毫升的細胞密度。使用新鮮培養基將懸浮液稀釋至細胞濃度為 1 × 10⁵ 個細胞/毫升,並將調整後的懸浮液分裝至新的燒瓶中,以供進一步培養。
- Thawing and culturing
Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.
Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.
For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.
Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.
Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.
Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.
Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.
Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.
07Quality control and cryopreservation
- Sterility
透過基於 PCR 的檢測及基於發光原理的支原體檢測方法,排除支原體污染的可能性。
為確保無細菌、真菌或酵母菌污染,每日均會對細胞培養物進行目視檢查。
- Freeze medium
- 作為冷凍保存培養基,我們使用完全生長培養基(含 FBS)+ 10% DMSO 以確保解凍後的存活率,或使用 CM-1 (Cytion 型號 800100),該培養基含有經優化的滲透保護劑和代謝穩定劑,可提升細胞恢復率並減輕冷凍誘導的壓力。
- Storage conditions
若需長期保存,請將試管置於溫度約為 −150 至 −196 °C 的氣相液氮中。僅在轉移至液氮之前,可將試管暫時存放於 −80 °C 環境中,作為短期過渡步驟。
- Shipping conditions
冷凍保存的細胞系會以乾冰冷藏,並裝於經驗證的隔熱包裝中,包裝內含有足夠的冷媒,以確保在運輸過程中溫度維持在約 −78 °C。收到貨物後,請立即檢查容器,並盡快將試管轉移至適當的儲存場所。
08Donor
- Donor age
- 30年
- Ethnicity
- 高加索人
09Legal and safety
- Safety precautions
- 若計劃將低溫試管存放在液態氮中以供日後解凍,必須嚴格遵守相關安全措施。 必須穿戴適當的防護手套和防護服,且在將冷凍樣本移入或移出液氮罐時,必須佩戴口罩或安全護目鏡。此舉旨在降低因取出時冷凍試管可能發生爆炸而導致受傷的風險,此類爆炸可能造成尖銳碎片飛濺。
- Warranty
在 Cytion,我們對產品的品質與存活率提供保障。 我們保證,自本公司設施出貨後 60 天內,我們的細胞在培養開始時仍具存活能力。 我們保證所有材料均符合 分析證明書及/或產品說明書中所載的規格。
詳情請參閱我們的 《保固聲明》。
- Third-party agreements apply
- Yes